GlassScriptPhysician profile
Joseph B Jacobs
NPI 1649234709
$12,885.91
in general payments reported to CMS, 2019-2025
25 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,786 · 2020: $1,276 · 2021: $2,342 · 2022: $2,780 · 2023: $2,221 · 2024: $322 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $2,980.26 | 2019-2023 | Trudi Nav Cable |
| Neurent Medical Limited | $2,430.03 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Intersect Ent, INC. | $2,313.61 | 2019-2022 | |
| Stryker Corporation | $2,167.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $896.06 | 2019-2024 | Jardiance |
| Arrinex, INC. | $293.50 | 2019 | |
| Medtronic USA, INC. | $286.70 | 2019-2020 | |
| Medtronic, INC. | $245.72 | 2021-2023 | Propel |
| Biocryst US Sales Co., LLC | $206.35 | 2021-2022 | |
| Amarin Pharma, INC. | $187.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $108.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.28 | 2022-2023 | |
| Genzyme Corporation | $107.94 | 2021-2022 | |
| Vifor Pharma, INC. | $104.19 | 2021 | |
| Aerin Medical INC. | $79.74 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $79.35 | 2023 | Xarelto |
| Amgen INC. | $47.96 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $47.54 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $42.94 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $41.03 | 2020-2022 | |
| Esperion Therapeutics, INC. | $25.56 | 2021 | |
| Pfizer INC. | $22.96 | 2021 | |
| Optinose US, INC. | $22.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.